Tests by Top Scientists at the ICDDRB Demonstrate the Superiority of Phlo's Oral Rehydration Solutions.

Business Editors & Health/Medical Writers

BUDD LAKE, N.J.--(BUSINESS WIRE)--June 4, 2003

Phlo Corporation (OTCBB:PHLC) ("Phlo") announced today that its Aquis Rapid Response Rehydration System ("Aquis") has been shown, in tests conducted by some of the world's top scientists in the rehydration field, to be superior to current solutions formulated in accordance with the World Health Organization's most advanced specifications. Tests recently conducted by a team of scientists at the International Center for Diarrheal Disease Research, Bangladesh ("ICDDRB"), demonstrate that the use of Aquis results in superior and faster absorption of both electrolytes and water as compared with the use of other leading oral rehydration solutions in the world, including those based on the World Health Organization's most advanced specifications. Additionally, Aquis has a superior taste, which is conducive to increased fluid intake by those drinking it.

The ICDDRB pioneered the discovery of oral rehydration solutions and recently received the Gates Award for Global Health in recognition of this contribution. The testing of Aquis conducted by the ICDDRB was directed by one of the world's leading specialists on rehydration, David A. Sack, M.D. Dr. Sack is the Director of the ICDDRB, where his work led to the validation of a vaccine now recommended by the World Health Organization.

One of the operating companies in Phlo's corporate group developed Aquis for use by the U.S. military and for humanitarian purposes. The company has the current capability to produce 130 million liters per year of Aquis and believes that such capacity could be doubled within 3 to 4 months. Aquis is available in ready-to-drink and powder forms.

There are two formulations of Aquis, one of which is directed to rehydration and one of which addresses diarrhea caused by diseases such as dysentery and cholera. Dehydration from these causes is a major problem for the U.S. Military, resulting in tremendous costs both in terms of dollars and loss of active personnel and is a major problem to be addressed on a humanitarian front as well.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patents-pending biotechnologies which are sold on a commercial basis to high-volume chain stores, such as supermarkets and drug and convenience stores. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.